Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06012435 | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer | PHASE3 | ACTIVE NOT_RECRUITING | 762 | — | — | Feb 21, 2024 | May 17, 2028 | May 27, 2026 | 334 | United States, Argentina +23 |
The time from date of randomization to date of death due to any cause.
| Arm | Type | Description |
|---|---|---|
| Experimental Arm | EXPERIMENTAL | sigvotatug vedotin monotherapy |
| Control Arm | ACTIVE_COMPARATOR | Docetaxel monotherapy |
| Name | Type | Description |
|---|---|---|
| sigvotatug vedotin | DRUG | Given into the vein (IV; intravenously) on Day 1 and 15 of a 28-day cycle |
| docetaxel | DRUG | 75 mg/m\^2 given into the vein (IV; intravenously) on Day 1 of a 21-day cycle |
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of locally advanced, unresectable (Stage IIIB, IIIC), or metastatic Stage IV (M1a, M1b, or M1c) NSCLC American Joint Committee on Cancer (AJCC) Staging Manual, Version 8.0, and the Union for International Cancer Control (UICC...